Chennai Meenakshi Multispeciality Share Price Today

Chennai Meenakshi Multispeciality Q2FY27 Results: Net loss widens to ₹29.45 lakh

Net loss widened to ₹29.45 lakh in Q2FY27 from a profit of ₹14.96 lakh in Q2FY26. Revenue from operations declined 8.7% YoY to ₹863.97 lakh. Employee benefits expenses dropped 17% YoY but failed to offset revenue shortfall. Cash and cash equivalents rose to ₹82.40 lakh as of September 30, 2026.

CMMH rejects five AGM resolutions including CMD reappointment

Five out of eight AGM resolutions rejected, including CMD reappointment. R V Ramanuja Bharathi appointed Independent Director for 5 years. Public shareholders opposed CMD reappointment with 63.29% opposition. Total votes cast at 36th AGM stood at 5,156,981.

Chennai Meenakshi Hospital sets Sept 30 AGM; book closure starts Sept 24

Chennai Meenakshi Multispeciality Hospital Ltd schedules its 36th AGM for September 30, 2026. Book closure for the meeting runs from September 24 to September 30, 2026. Agenda includes reappointment of MD R. Gomathi and reshuffling of board directors. Company reported a narrowed net loss of ₹111.72 lakhs in FY26 versus ₹137.37 lakhs in FY25.

Chennai Meenakshi Multispeciality board meeting rescheduled to September 1

Board meeting postponed from August 28 to September 1, 2026. Postponement due to unavoidable administrative reasons. Agenda includes approval of FY26 annual results. Directors to fix date and mode for 36th AGM.

Chennai Meenakshi Multispeciality Q1 Results: Net profit turns positive

Chennai Meenakshi Multispeciality Hospital Limited posted a net profit of ₹0.28 lakh in Q1FY27, reversing a ₹74.11 lakh loss from the prior year. Revenue was ₹859.02 lakh. The Board appointed Dr Thanigai Vendan Moorrthy as CEO and three independent directors, reconstituting key committees.

Chennai Meenakshi appoints M. Karunakaran as independent director

Chennai Meenakshi Multispeciality Hospital Limited appointed M. Karunakaran as an Additional Non-Executive Independent Director for a five-year term starting August 7, 2026. The Board reconstituted the Audit, Nomination and Remuneration, and Stakeholders Relationship Committees accordingly. The appointment is subject to shareholder approval at the next AGM.